Companies with a Future performance score of at least 3, ordered by Future performance score.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs.
Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia.
Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia.
Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia.
Palla Pharma Limited, a vertically integrated pharmaceutical company, produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines.
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates.
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices.
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.
Ecofibre Limited, together with its subsidiaries, engages in breeding, growing, processing, and distributing hemp products in the United States and Australia.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide.
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia.
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.